denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Thursday, December 5, 2019
3:00 PM-7:00 PM
Friday, December 6, 2019
7:00 AM-9:30 AM
7:00 AM-11:00 AM
AML: Expert Guidance on Current Standards and New Directions in Patient Care
Friday Satellite Symposia
Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
Friday Satellite Symposia
Current Status of Clinical Laboratory Testing of Plasma Cell Neoplasms: A Case-Based Approach
Friday Satellite Symposia
Disease Modification in Sickle Cell Disease: Mechanisms, Advances and Clinical Implications
Friday Satellite Symposia
Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research
Friday Satellite Symposia
7:00 AM-6:00 PM
9:00 AM-12:00 PM
12:30 PM-3:00 PM
12:30 PM-3:30 PM
12:30 PM-4:30 PM
Advancing Science in Sickle Cell Disease: Implications for the Future of Care
Friday Satellite Symposia
Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders
Friday Satellite Symposia
CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia – Clinical Updates and Innovations
Friday Satellite Symposia
Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies
Friday Satellite Symposia
Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges
Friday Satellite Symposia
Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy
Friday Satellite Symposia
New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
Friday Satellite Symposia
Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
Friday Satellite Symposia
12:45 PM-1:00 PM
ASH-a-Palooza
1:00 PM-1:05 PM
1:00 PM-1:10 PM
1:00 PM-1:15 PM
ASH-a-Palooza
1:05 PM-1:25 PM
1:05 PM-1:40 PM
1:05 PM-2:00 PM
1:05 PM-2:05 PM
Epidemiology of Lymphoid Malignancy and Benign Hematologic Disorders - Part 1
Friday Scientific Workshops
1:10 PM-1:50 PM
1:25 PM-1:40 PM
1:25 PM-2:00 PM
1:30 PM-1:35 PM
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
1:30 PM-1:45 PM
ASH-a-Palooza
1:30 PM-2:00 PM
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
Blood Buddies: Laboratory/Translational Hematology & Quality Improvement
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
1:40 PM-2:00 PM
1:40 PM-2:30 PM
1:45 PM-1:50 PM
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
1:45 PM-2:00 PM
ASH-a-Palooza
1:55 PM-2:35 PM
2:00 PM-2:15 PM
2:00 PM-2:30 PM
Syndromes with Complex Pathophysiology: MECOM Mutations and other Exciting Discoveries
Friday Scientific Workshops
2:00 PM-5:00 PM
K2R Workshop
2:05 PM-2:15 PM
2:05 PM-2:20 PM
ASH-a-Palooza
2:05 PM-2:25 PM
2:05 PM-2:35 PM
2:15 PM-2:35 PM
2:15 PM-3:00 PM
Epidemiology of Lymphoid Malignancy and Benign Hematologic Disorders - Part 2
Friday Scientific Workshops
2:15 PM-3:05 PM
2:20 PM-3:30 PM
2:30 PM-2:35 PM
ASH-a-Palooza
ASH-a-Palooza
Blood Drop: Clinical Practice Guidelines: What are they and why do they matter?
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
2:30 PM-2:40 PM
2:30 PM-2:45 PM
ASH-a-Palooza
2:30 PM-3:00 PM
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
Blood Buddies: Laboratory/Translational Hematology & Quality Improvement
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
2:30 PM-3:15 PM
Let Us Walk Together: International Collaborations To Advance Knowledge About Predisposition Syndromes
Friday Scientific Workshops
2:35 PM-2:50 PM
2:35 PM-3:35 PM
2:40 PM-3:20 PM
2:40 PM-3:55 PM
Interplay Between the Coagulation System and Solid Tumor Progression - Part 1
Friday Scientific Workshops
2:45 PM-2:50 PM
ASH-a-Palooza
ASH-a-Palooza
Blood Drop: Clinical Practice Guidelines: What are they and why do they matter?
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
2:45 PM-3:00 PM
ASH-a-Palooza
2:55 PM-3:45 PM
3:00 PM-3:10 PM
Panel Discussion: Integrating Study of Rare Diseases with Population Studies
Friday Scientific Workshops
3:00 PM-3:15 PM
ASH-a-Palooza
3:05 PM-3:20 PM
3:05 PM-3:25 PM
3:15 PM-3:30 PM
3:25 PM-3:40 PM
3:25 PM-4:10 PM
3:30 PM-3:35 PM
ASH-a-Palooza
Blood Drop: ASH and EHA Translational Research Training Institute Award
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
3:30 PM-3:45 PM
3:30 PM-4:00 PM
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
Blood Buddies: Laboratory/Translational Hematology & Quality Improvement
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
3:30 PM-4:20 PM
3:35 PM-4:05 PM
3:35 PM-4:25 PM
Lymphoma and Chronic Lymphocytic Leukemia: Mechanisms of Efficacy and Toxicity
Friday Scientific Workshops
3:40 PM-3:45 PM
ASH-a-Palooza
3:40 PM-4:00 PM
3:45 PM-3:50 PM
ASH-a-Palooza
Blood Drop: ASH and EHA Translational Research Training Institute Award
Trainee Activities and Services
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
ASH-a-Palooza
3:45 PM-3:55 PM
3:45 PM-4:30 PM
Bringing Light into Darkness: Systematic Genotyping and Expert Variant Curation
Friday Scientific Workshops
3:55 PM-4:15 PM
3:55 PM-4:45 PM
4:00 PM-4:15 PM
4:05 PM-4:45 PM
Chimeric Antigen Receptor T Cell Therapy for PCD With an Emphasis on Multiple Myeloma
Friday Scientific Workshops
4:05 PM-5:05 PM
4:10 PM-4:20 PM
4:15 PM-4:25 PM
4:20 PM-4:45 PM
4:25 PM-4:40 PM
How to Define the Curative Threshold: Is a Hemoglobin Electrophoresis Enough?
Friday Scientific Workshops
4:30 PM-4:55 PM
Ethical Considerations Surrounding Somatic and Germline Testing for Individuals with Hematologic Malignancies
Friday Scientific Workshops
4:30 PM-5:10 PM
4:30 PM-5:15 PM
Interplay Between the Coagulation System and Solid Tumor Progression - Part 2
Friday Scientific Workshops
4:40 PM-4:50 PM
4:40 PM-5:15 PM
4:45 PM-4:55 PM
4:45 PM-5:00 PM
4:55 PM-5:00 PM
4:55 PM-5:15 PM
4:55 PM-5:30 PM
5:00 PM-5:40 PM
5:05 PM-5:35 PM
5:05 PM-5:55 PM
5:15 PM-5:30 PM
5:15 PM-5:35 PM
5:15 PM-5:55 PM
Beyond Myeloid Predisposition: Germline Susceptibility to Lymphoid and Solid Malignancies
Friday Scientific Workshops
5:30 PM-5:40 PM
5:30 PM-5:45 PM
5:35 PM-5:40 PM
5:40 PM-5:55 PM
5:45 PM-5:50 PM
5:45 PM-5:55 PM
5:55 PM-6:00 PM
6:00 PM-8:00 PM
6:00 PM-10:00 PM
Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going
Friday Satellite Symposia
Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management
Friday Satellite Symposia
Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care
Friday Satellite Symposia
The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!
Friday Satellite Symposia
Moving From Science Fiction to Clinical Reality: Gene Therapy for Beta-Hemoglobinopathies
Friday Satellite Symposia
MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis
Friday Satellite Symposia
Saturday, December 7, 2019
7:00 AM-7:45 AM
7:00 AM-6:00 PM
7:30 AM-9:00 AM
613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes
Oral and Poster Abstracts
621. Lymphoma—Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis
Oral and Poster Abstracts
632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes
Oral and Poster Abstracts
801. Gene Therapy and Transfer: Advancing CAR T Cells: New Biology and Therapeutic Applications
Oral and Poster Abstracts
901. Health Services Research—Non-Malignant Conditions: Bleeding and Blood Loss
Oral and Poster Abstracts
9:00 AM-9:15 AM
ASH Wellness Studio - Think Well: Stress - Why Manage What You Can Prevent?
Special-Interest Sessions
9:00 AM-9:30 AM
9:00 AM-7:30 PM
9:15 AM-9:30 AM
9:30 AM-11:00 AM
311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP
Oral and Poster Abstracts
401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences
Oral and Poster Abstracts
508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment
Oral and Poster Abstracts
732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens
Oral and Poster Abstracts
9:30 AM-11:30 AM
11:00 AM-11:15 AM
11:00 AM-12:30 PM
11:00 AM-5:00 PM
11:15 AM-11:30 AM
11:15 AM-12:15 PM
Approach to Diagnosis and Management of Patients with Congenital Platelet Disorders
How I Treat: Bringing Science to Clinical Dilemmas
Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies
Continuing Conversations With the Speakers
Hypereosinophilia: An Approach to Diagnosis and Management
How I Treat: Bringing Science to Clinical Dilemmas
Implementation of Direct Oral Anticoagulant Reversal Agents in the Critical Care Setting
How I Treat: Bringing Science to Clinical Dilemmas
Strategy for Diagnosis and Management of Bone Marrow Failure Syndromes
How I Treat: Bringing Science to Clinical Dilemmas
Update on Complement Inhibition in PNH, Atypical HUS, and other Hemolytic Anemias
How I Treat: Bringing Science to Clinical Dilemmas
What’s New in the Diagnosis and Treatment of HLH?
How I Treat: Bringing Science to Clinical Dilemmas
11:30 AM-11:45 AM
11:30 AM-12:30 PM
Continuing Conversations With the Speakers on Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches
Continuing Conversations With the Speakers
11:45 AM-12:00 PM
12:00 PM-12:15 PM
ASH Wellness Studio - Think Well: Stress - Why Manage What You Can Prevent?
Special-Interest Sessions
12:00 PM-1:30 PM
322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms
Oral and Poster Abstracts
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases I
Oral and Poster Abstracts
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies
Oral and Poster Abstracts
12:15 PM-12:30 PM
12:30 PM-12:45 PM
12:45 PM-1:45 PM
1:30 PM-1:45 PM
1:30 PM-2:00 PM
1:45 PM-2:00 PM
2:00 PM-3:30 PM
201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions
Oral and Poster Abstracts
311. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders
Oral and Poster Abstracts
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations
Oral and Poster Abstracts
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes
Oral and Poster Abstracts
Special Symposium on Quality: ASH EQUIPS - Learning from Medical Errors and Other Incidents
Special-Interest Sessions
3:30 PM-3:45 PM
3:30 PM-4:00 PM
3:45 PM-4:00 PM
4:00 PM-5:30 PM
613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy
Oral and Poster Abstracts
625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Targeting Apoptosis Pathways in Lymphoma
Oral and Poster Abstracts
635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms
Oral and Poster Abstracts
901. Health Services Research—Non-Malignant Conditions: Cancers and Thrombosis
Oral and Poster Abstracts
4:00 PM-6:00 PM
5:30 PM-7:30 PM
113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster I
Oral and Poster Abstracts
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster I
Oral and Poster Abstracts
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
Oral and Poster Abstracts
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster I
Oral and Poster Abstracts
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I
Oral and Poster Abstracts
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I
Oral and Poster Abstracts
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Oral and Poster Abstracts
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Oral and Poster Abstracts
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
Oral and Poster Abstracts
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Oral and Poster Abstracts
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I
Oral and Poster Abstracts
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Oral and Poster Abstracts
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I
Oral and Poster Abstracts
903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I
Oral and Poster Abstracts
6:30 PM-7:30 PM
6:30 PM-7:45 PM
6:30 PM-9:00 PM
Sunday, December 8, 2019
7:00 AM-9:00 AM
7:00 AM-5:00 PM
7:00 AM-6:00 PM
7:30 AM-8:30 AM
7:30 AM-9:00 AM
642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment
Oral and Poster Abstracts
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Omic-Driven Insight into Pathogenesis
Oral and Poster Abstracts
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials
Oral and Poster Abstracts
803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases
Oral and Poster Abstracts
Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management?
Special Scientific Symposia
8:30 AM-9:30 AM
9:00 AM-9:15 AM
ASH Wellness Studio - Think Well: The Life Enhancing Power of 'Compassionomics'
Special-Interest Sessions
9:00 AM-9:30 AM
9:00 AM-8:00 PM
9:15 AM-9:30 AM
9:30 AM-11:00 AM
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery
Oral and Poster Abstracts
Lost in Translation: Overcoming Roadblocks in Translating New Therapeutics to the Clinic
Special Scientific Symposia
9:30 AM-11:15 AM
802. Chemical Biology and Experimental Therapeutics: Novel Compounds and Mechanisms of Action
Oral and Poster Abstracts
9:30 AM-11:30 AM
10:00 AM-5:00 PM
11:00 AM-11:15 AM
11:00 AM-12:30 PM
11:15 AM-11:30 AM
11:15 AM-12:15 PM
Approach to the Patient with Microangiopathic Hemolytic Anemia
How I Treat: Bringing Science to Clinical Dilemmas
Continuing Conversations With the Speakers on Chromatin Structure in Development and Disease
Continuing Conversations With the Speakers
Continuing Conversations With the Speakers on Ex Vivo Bioengineering of Blood Products for Transfusion
Continuing Conversations With the Speakers
Defining Treatment Strategies for MDS/MPN Overlap Syndromes
How I Treat: Bringing Science to Clinical Dilemmas
How to Interpret Next Generation Sequencing Panels in Patients with CHIP and Hematolymphoid Neoplasms
How I Treat: Bringing Science to Clinical Dilemmas
Monoclonal Gammopathies of Cutaneous, Neuropathic, and Renal Significance
How I Treat: Bringing Science to Clinical Dilemmas
Trainee Didactic Session
Trainee Didactic Session
Trainee Didactic Session 2: Application of Microarray and Large Datasets to Hematology and Bioinformatics
Trainee Activities and Services
11:15 AM-12:30 PM
11:30 AM-12:00 PM
ASH Wellness Studio - Meditation without Robes and Incense: Simple Steps to Meditation
Special-Interest Sessions
11:30 AM-12:30 PM
12:00 PM-12:15 PM
12:00 PM-1:30 PM
102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease
Oral and Poster Abstracts
201. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia
Oral and Poster Abstracts
331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment
Oral and Poster Abstracts
508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure
Oral and Poster Abstracts
Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease
Special-Interest Sessions
12:15 PM-12:30 PM
12:30 PM-1:30 PM
1:30 PM-2:00 PM
2:00 PM-4:00 PM
4:00 PM-4:15 PM
4:00 PM-4:30 PM
4:15 PM-4:30 PM
4:30 PM-6:00 PM
321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation
Oral and Poster Abstracts
642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL
Oral and Poster Abstracts
Special Education Session on ASH Clinical Practice Guidelines on Immune Thrombocytopenia
Special-Interest Sessions
4:30 PM-6:30 PM
TRTH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research
Special-Interest Sessions
6:00 PM-8:00 PM
113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster II
Oral and Poster Abstracts
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster II
Oral and Poster Abstracts
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
Oral and Poster Abstracts
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster II
Oral and Poster Abstracts
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II
Oral and Poster Abstracts
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster II
Oral and Poster Abstracts
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Oral and Poster Abstracts
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
Oral and Poster Abstracts
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
Oral and Poster Abstracts
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Oral and Poster Abstracts
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster II
Oral and Poster Abstracts
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
Oral and Poster Abstracts
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster II
Oral and Poster Abstracts
903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster II
Oral and Poster Abstracts
Monday, December 9, 2019
7:00 AM-7:45 AM
7:00 AM-8:30 AM
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells
Oral and Poster Abstracts
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies
Oral and Poster Abstracts
621. Lymphoma—Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches
Oral and Poster Abstracts
634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies
Oral and Poster Abstracts
801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders
Oral and Poster Abstracts
Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults
Special-Interest Sessions
7:00 AM-11:30 AM
7:00 AM-5:00 PM
9:00 AM-10:00 AM
10:00 AM-10:15 AM
10:00 AM-10:30 AM
10:00 AM-2:00 PM
10:00 AM-8:00 PM
10:15 AM-10:30 AM
10:30 AM-12:00 PM
322. Disorders of Coagulation or Fibrinolysis: Clinical Trials and Improving Care Delivery
Oral and Poster Abstracts
331. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis
Oral and Poster Abstracts
634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
Oral and Poster Abstracts
637. Myelodysplastic Syndromes—Clinical Studies: Targeting Gene Mutations in MDS
Oral and Poster Abstracts
653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma
Oral and Poster Abstracts
ASH Choosing Wisely® Campaign: The ASH-ASPHO Pediatric Choosing Wisely List
Special-Interest Sessions
12:00 PM-1:30 PM
12:15 PM-12:30 PM
ASH Wellness Studio - Think Well: Stress - Why Manage What You Can Prevent?
Special-Interest Sessions
12:15 PM-1:15 PM
Trainee Didactic Session
Trainee Didactic Session 3: How to Set up a Health Services and Outcomes Research Program
Trainee Activities and Services
Trainee Didactic Session
Trainee Didactic Session 4: Bridging the Translational Divide: The Role of the PhD
Trainee Activities and Services
12:30 PM-12:45 PM
12:30 PM-1:30 PM
12:45 PM-1:00 PM
1:00 PM-1:15 PM
1:30 PM-2:30 PM
2:30 PM-2:45 PM
2:45 PM-3:00 PM
2:45 PM-4:15 PM
401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences
Oral and Poster Abstracts
613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease
Oral and Poster Abstracts
636. Myelodysplastic Syndromes—Basic and Translational Studies: RNA Processing and Signatures in MDS
Oral and Poster Abstracts
901. Health Services Research—Non-Malignant Conditions: Improving Quality in Hematology
Oral and Poster Abstracts
Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism
Special-Interest Sessions
4:15 PM-4:45 PM
4:30 PM-6:00 PM
112. Thalassemia and Globin Gene Regulation: Hemoglobin Regulation and Beta Thalassemia Research
Oral and Poster Abstracts
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases II
Oral and Poster Abstracts
612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies
Oral and Poster Abstracts
634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need
Oral and Poster Abstracts
641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution
Oral and Poster Abstracts
703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches
Oral and Poster Abstracts
802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening
Oral and Poster Abstracts
4:30 PM-6:30 PM
6:00 PM-8:00 PM
113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III
Oral and Poster Abstracts
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster III
Oral and Poster Abstracts
605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III
Oral and Poster Abstracts
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
Oral and Poster Abstracts
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III
Oral and Poster Abstracts
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Oral and Poster Abstracts
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Oral and Poster Abstracts
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
Oral and Poster Abstracts
636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
Oral and Poster Abstracts
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III
Oral and Poster Abstracts
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster III
Oral and Poster Abstracts
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
Oral and Poster Abstracts
902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster III
Oral and Poster Abstracts
903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
Oral and Poster Abstracts
905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III
Oral and Poster Abstracts
6:15 PM-7:45 PM
322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications
Oral and Poster Abstracts
621. Lymphoma—Genetic/Epigenetic Biology: DLBCL Genomics and Molecular Signatures
Oral and Poster Abstracts
653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma
Oral and Poster Abstracts